Adaptimmune Therapeutics PLC (ADAP) Receives Buy Rating from SunTrust Banks, Inc.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP)‘s stock had its “buy” rating reiterated by analysts at SunTrust Banks, Inc. in a research report issued to clients and investors on Thursday. They presently have a $10.00 target price on the biotechnology company’s stock. SunTrust Banks, Inc.’s price target indicates a potential upside of 28.87% from the stock’s previous close.
Several other equities research analysts have also recently weighed in on ADAP. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Wednesday, July 12th. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $11.58.
Shares of Adaptimmune Therapeutics PLC (ADAP) traded down 1.02% during trading on Thursday, hitting $7.76. 256,152 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $8.41 and a 200-day moving average price of $8.41. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $9.29. The stock’s market cap is $725.71 million.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. The firm had revenue of $3.52 million during the quarter, compared to analysts’ expectations of $5.43 million. Equities research analysts expect that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. NEA Management Company LLC lifted its position in Adaptimmune Therapeutics PLC by 21.7% during the first quarter. NEA Management Company LLC now owns 12,025,999 shares of the biotechnology company’s stock valued at $66,263,000 after acquiring an additional 2,145,000 shares during the last quarter. Matrix Capital Management Company LP purchased a new stake in Adaptimmune Therapeutics PLC during the second quarter valued at approximately $39,027,000. Capital World Investors lifted its position in Adaptimmune Therapeutics PLC by 168.4% during the fourth quarter. Capital World Investors now owns 4,601,000 shares of the biotechnology company’s stock valued at $55,488,000 after acquiring an additional 2,887,082 shares during the last quarter. Tekla Capital Management LLC lifted its position in Adaptimmune Therapeutics PLC by 158.9% during the first quarter. Tekla Capital Management LLC now owns 1,466,368 shares of the biotechnology company’s stock valued at $8,080,000 after acquiring an additional 900,000 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its position in Adaptimmune Therapeutics PLC by 43.7% during the second quarter. Baillie Gifford & Co. now owns 1,323,308 shares of the biotechnology company’s stock valued at $5,941,000 after acquiring an additional 402,324 shares during the last quarter. 68.01% of the stock is owned by institutional investors.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.